Abstract
Acute cardiogenic shock (aCS) is associated with high rates of morbidity and mortality despite advancements in therapy. The development of ventricular assist devices (VADs) has emerged as an effective option to rescue patients from circulatory collapse following myocardial infarction, acute myocarditis, or post-cardiotomy shock. The HeartMate II left ventricular assist device (HM-II LVAD) has not been formally studied for use in aCS. We hypothesized that survival with the HM-II LVAD used as the primary mechanical assist device in aCS would be superior to other mechanical circulatory support (MCS) strategies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
